KD-PACE salvage therapy for aggressive relapsed multiple myeloma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2019)
摘要
The non-cross-resistant combination VDT-PACE (bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide) incorporating novel and traditional anti-MM drugs has been evaluated for relapsed and/or refractory myeloma (RRMM) or aggressive clinical situations such as plasma cell leukemia (PCL) or extramedullary myeloma (EMM). However, in the modern era, many patients are already refractory to bortezomib when this therapy is utilized. Outcomes from incorporation of carfilzomib (KD-PACE) instead of bortezomib as salvage therapy for relapsed aggressive MM are described.
更多查看译文
关键词
carfilzomib,relapsed/refractory multiple myeloma,transplantation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要